# Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

> **NCT00943072** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 189 (actual)

## Conditions studied

- Macular Edema Secondary to Central Retinal Vein Occlusion

## Interventions

- **BIOLOGICAL:** VEGF Trap-Eye 2.0mg
- **DRUG:** Sham

## Key facts

- **NCT ID:** NCT00943072
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-10
- **Final completion:** 2012-04
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2013-05-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00943072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00943072, "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00943072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*